Zolbetuximab for gastroesophageal adenocarcinoma: drug review and lessons from the frontlines

Keyphrases

• Gastroesophageal Adenocarcinoma 100%
• Drug Review 100%
• Zolbetuximab 100%
• Claudin 18.2 60%
• Fluoropyrimidine 40%
• Advanced Gastric Adenocarcinoma 40%
• Gastric or Gastroesophageal Junction Adenocarcinoma 40%
• Monoclonal Antibody 20%
• Clinical Practice 20%
• Malignancy 20%
• Stomach 20%
• Tumor Cells 20%
• Vomiting 20%
• Nausea 20%
• Adverse Events 20%
• Phase II Trial 20%
• Initial Treatment 20%
• Gastric Adenocarcinoma 20%
• Tolerability 20%
• Gastrointestinal Tract 20%
• Improved Outcomes 20%
• Observation Time 20%
• Prior Surgery 20%
• Multiple Agents 20%
• Treatment Decisions 20%
• Treatment Cycle 20%
• Administration Time 20%
• Drug Stability 20%
• Drug Evaluation 20%
• Real-world Implementation 20%
• FDA Approval 20%
• Molecular Distinction 20%
• Platinum-based Therapy 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Adenocarcinoma 100%
• Zolbetuximab 100%
• Stomach Adenocarcinoma 60%
• Claudin 60%
• Fluoropyrimidine 40%
• Platinum 40%
• Neoplasm 20%
• Monoclonal Antibody 20%
• Adverse Event 20%
• Nausea and Vomiting 20%
• Tolerability 20%
• Drug Screening 20%
• Patient History of Surgery 20%
• Drug Stability 20%
• Phase III Trials 20%